Laurus Labs Ltd (LAURUSLABS)
₹1,940.70
Mkt cap
₹1.01L Cr
P/E ratio
92.70
P/B
19.76
Div yield
0.11%
ROE
18.30%
ROCE
17.80%
EPS (TTM)
₹20.94
Book value
₹98
52W range
832–1,941
Sector
Healthcare
Price history
Previous close
Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (including High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug development to commercial manufacturing. Laurus employs 6,500+ people, including around 1,050+ scientists, at more than 11 facilities approved by global agencies USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, TGA etc. [1]
NSE LAURUSLABSBSE 540222
Health check
Constructive
ValuationExpensive
ProfitabilityStrong
GrowthHigh
TechnicalsBullish
52-week range
0.00% from high₹1,941
₹832+133.17% from low₹1,941
Current
₹1,940.70
Prev close
₹1,876.70
Day
+3.41%
Price performance
1D
+3.41%
1W
+4.25%
1M
+4.68%
3M
+40.05%
6M
+85.55%
1Y
+125.64%
YTD
+75.39%
Financials
Revenue, profit & margin
P/E ratio
92.7×
LAURUSLABS is 163% above the sector median of 35.2×
LAURUSLABS92.7×
Sector median35.2×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,182 | 1,224 | 1,195 | 1,440 | 1,195 | 1,224 | 1,415 | 1,720 | 1,570 | 1,653 | 1,778 | 1,812 | 2,026 | |
| Expenses | 1,015 | 1,037 | 1,014 | 1,198 | 1,024 | 1,045 | 1,130 | 1,300 | 1,187 | 1,250 | 1,298 | 1,299 | 1,388 | |
| Operating Profit | 167 | 188 | 181 | 241 | 171 | 178 | 285 | 421 | 382 | 403 | 480 | 512 | 638 | |
| OPM % | 14% | 15% | 15% | 17% | 14% | 15% | 20% | 24% | 24% | 24% | 27% | 28% | 32% | |
| Other Income | 4 | 2 | 2 | 19 | 3 | 5 | 9 | 59 | 10 | 27 | 6 | 12 | 9 | |
| Interest | 39 | 42 | 51 | 50 | 49 | 53 | 58 | 56 | 52 | 40 | 39 | 40 | 42 | |
| Depreciation | 91 | 93 | 98 | 102 | 106 | 108 | 106 | 110 | 117 | 120 | 121 | 122 | 124 | |
| Profit before tax | 41 | 54 | 35 | 107 | 18 | 23 | 131 | 312 | 224 | 270 | 327 | 361 | 481 | |
| Tax % | 30% | 27% | 27% | 30% | 34% | 22% | 31% | 25% | 28% | 28% | 22% | 22% | 25% | |
| Net Profit | 27 | 37 | 23 | 75 | 13 | 20 | 93 | 233 | 162 | 194 | 252 | 282 | 362 | |
| EPS in Rs | 0.46 | 0.69 | 0.43 | 1.40 | 0.23 | 0.37 | 1.71 | 4.33 | 3.02 | 3.61 | 4.66 | 5.17 | 6.80 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +0.15% · closed higher next day 22 of last 43
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26† | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 20 Oct '23◦ | 24 Jan '24◦ | 25 Apr '24◦ | 25 Jul '24◦ | 24 Oct '24◦ | 24 Jan '25◦ | 25 Apr '25 | 25 Jul '25 | 23 Oct '25 | 23 Jan '26 | 30 Apr '26 | 24 Jul '26 |
| Earnings day | −9.61% | −5.51% | +2.59% | +3.50% | +4.14% | −11.28% | −3.08% | +0.15% | +1.49% | +1.05% | −0.47% | +2.10% |
| +1 day | −11.05% | −6.66% | +4.19% | +3.95% | +10.04% | −15.25% | −2.94% | +6.31% | +0.62% | −0.56% | +5.45% | +9.25% |
| +5 days | −9.78% | −2.07% | +3.12% | +3.05% | +8.98% | −1.17% | −4.29% | +1.54% | +5.40% | −5.16% | +11.05% | +15.81% |
| +15 days | −7.73% | −0.26% | +4.40% | +0.65% | +9.32% | −9.37% | −5.91% | +3.48% | +8.51% | +0.66% | +21.46% | +13.96% |
| +30 days | −2.72% | +2.23% | +4.17% | +13.16% | +28.05% | −7.24% | +3.38% | +7.87% | +11.45% | +3.20% | +25.59% | +17.32% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Interim Dividend - Rs 1.20 Per Share | 1.20 | 8 May '26 | 8 May '26 |
Shareholding
as of Jun 202627.47%Promoter
Promoters27.47%0.02
FIIs28.00%2.18
DIIs13.73%0.23
Public30.79%1.94
Ownership trend
Peers
7 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,895.00 | 35.99 | 4,54,674 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,315.00 | 83.00 | 2,47,284 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,914.00 | 83.89 | 1,87,183 | 0.77% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| ZYDUSLIFE | ₹1,156.90 | 23.70 | 1,15,401 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| CIPLA | ₹1,395.00 | 31.49 | 1,12,696 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| LAURUSLABS | ₹1,876.70 | 92.74 | 1,01,400 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,105.00 | 16.17 | 96,254 | 0.86% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| Median: 158 Co. | ₹426.15 | 35.20 | 2,303 | 0.08% | 13 | +30.25% | 164 | +18.67% | 14.96% |
Filings
Annual reports13
Concall transcripts94
TranscriptJul 2026PPTJul 2026RECJul 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptJan 2026PPTJan 2026RECJan 2026TranscriptOct 2025PPTOct 2025RECOct 2025PPTSep 2025TranscriptJul 2025PPTJul 2025TranscriptApr 2025PPTApr 2025RECApr 2025TranscriptJan 2025PPTJan 2025RECJan 2025PPTJan 2025TranscriptOct 2024PPTOct 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 31 AugAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 12 AugIntimation Of ESG Score Given By NSE Sustainability Ratings And Analytics Limited 10 Aug - NSE Sustainability assigned Laurus Labs an ESG score of 63/100 for FY2026.Announcement under Regulation 30 (LODR)-Earnings Call Transcript 30 JulAnnouncement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 27 Jul